Harrow (HROW) Income towards Parent Company (2010 - 2026)
Harrow's (HROW) quarterly Income towards Parent Company came in at -$27.6 million in Q1 2026, down 55.24% year-on-year from -$61.7 million in Q1 2025, and down 365.48% quarter-over-quarter from $10.4 million in Q4 2025.
Harrow (HROW) Income towards Parent Company (2010 - 2026) Analysis & Trends
Harrow's Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$27.6 million for Q1 2026.
- On a quarterly basis, Income towards Parent Company fell 55.24% year-over-year to -$27.6 million in Q1 2026; TTM through Mar 2026 was -$11.2 million, a 48.42% increase from a year earlier, with the FY2025 full-year figure at -$5.1 million, up 70.6% from the prior year.
- Income towards Parent Company fell to -$27.6 million in Q1 2026 per HROW's latest filing, from $10.4 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $10.4 million in Q4 2025 and bottomed at -$27.6 million in Q1 2026.
- The 5-year median for Income towards Parent Company is -$4.4 million (2023), against an average of -$5.0 million.
- Across the five-year window, Income towards Parent Company plunged 1223.5% in 2022 and surged 177.17% in 2025, its largest moves.
- Year by year, Income towards Parent Company stood at $1.1 million in 2022, then plunged by 967.11% to -$9.1 million in 2023, then surged by 174.08% to $6.8 million in 2024, then surged by 53.42% to $10.4 million in 2025, then plunged by 365.48% to -$27.6 million in 2026.
- Per Business Quant, the three latest HROW Income towards Parent Company figures stand at -$27.6 million (Q1 2026), $10.4 million (Q4 2025), and $1.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.91 Bn | 88.04 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.17 Bn | 1.97 Bn |
| 3 | Zoetis | 32.54 Bn | 30.60 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.05 Bn | 20.89 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.82 Bn | 16.50 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Harrow | 1.42 Bn | 1.32 Bn | 27.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.60 Mn |
| Dec 31, 2025 | 10.40 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 5.00 Mn |
| Mar 31, 2025 | -17.78 Mn |
| Dec 31, 2024 | 6.78 Mn |
| Sep 30, 2024 | -4.22 Mn |
| Jun 30, 2024 | -6.47 Mn |
| Mar 31, 2024 | -13.57 Mn |
| Dec 31, 2023 | -9.15 Mn |
| Sep 30, 2023 | -4.39 Mn |
| Jun 30, 2023 | -4.23 Mn |
| Mar 31, 2023 | -6.64 Mn |
| Dec 31, 2022 | 1.06 Mn |
| Sep 30, 2022 | -6.46 Mn |
| Jun 30, 2022 | -6.24 Mn |
| Mar 31, 2022 | -2.44 Mn |
| Dec 31, 2021 | -7.29 Mn |
| Sep 30, 2021 | -8.33 Mn |
| Jun 30, 2021 | -2.48 Mn |